Ventricular Assist Device Market Size, Share & Industry Analysis, By Product (Left Ventricular Assist Device, Right Ventricular Assist Device, and Bi-Ventricular Assist Device), By Type of Flow (Pulsatile Flow and Continuous Flow), By Application (Bridge to Transplant (BTT), Bridge to Candidacy (BTC), Destination Therapy (DT), and Bridge to Recovery (BTR)), By End-user (Hospitals & ASCs and Specialty Clinics & Others), and Regional Forecast, 2026-2034

The ventricular assist device market size was valued at USD 1.49 billion in 2025. The market is projected to grow from USD 1.64 billion in 2026 to USD 3.54 billion by 2034, exhibiting a CAGR of 10.1% during the forecast period.

Ventricular assist devices (VAD) are implanted in heart failure patients with severe symptoms to provide them with mechanical circulatory support by pumping blood from the chambers of the heart to the whole body. The increasing prevalence of heart failure has been fueling the demand for these devices globally.

• For instance, as per data published by the Journal of Cardiac Failure in 2023, around 6.7 million Americans aged 20 and above suffer from heart failure. Moreover, this number is expected to reach 8.5 million by 2030.

Abbott, ABIOMED, and Berlin Heart held the largest global market share in 2025. The market players’ increased focus on R&D initiatives to develop efficient devices is contributing to their dominance.

• For instance, in August 2022, Abbott announced the results of the patients implanted with its HeartMate 3 left ventricular assist devices. The patients showed better survival rates with the implantation of this device, which will increase the adoption of the product.

Download Free sample to learn more about this report.

VENTRICULAR ASSIST DEVICE MARKET TRENDS

Increasing Technological Developments to Fuel the Demand for Mechanical Circulatory Support System

Technological advancements in the healthcare industry are assisting healthcare professionals to record and monitor clinical data regularly through artificial intelligence with minimal errors. The high-performance capabilities of artificial intelligence (AI) algorithms will transform the market outlook.

AI can be helpful in determining the risk of cardiovascular diseases, which can be used to enhance risk prediction and treatment among patients. It can also be utilized during surgeries to analyze the patient’s anatomy, risk factors, history of disease, and other factors, which can enhance the results of the surgeries.

In cardiothoracic surgery, machine learning algorithms can outperform standard operative risk scores in predicting intra-hospital mortality after cardiac procedures. Thus, the development of technology in cardiac procedures is likely to propel ventricular assist device adoption.

Technological developments in medical devices have enhanced the efficiency of these devices. Thus, the rate of infection through the devices is reduced simultaneously. Latest devices, such as HeartMate III and DuraHeart, have features such as lower rotational speeds, smaller sizes, higher efficiency, and enhanced anatomic design. The LVAD pump is surgically implanted inside the patient's body and connected to an external controller and power source through a percutaneous driveline that exits through the skin. It provides mechanical circulatory support to patients with weakened hearts and helps pump oxygenated blood from the left ventricle into the ascending aorta. Thus, the development of these effective devices in the market is expected to propel the market growth during the forecast period.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Prevalence of Heart Failure to Increase the Demand for VAD

Heart failure is one of the leading causes of mortality worldwide, affecting more than 1-2% of the population in Western countries. For instance, the American Heart Association reported in May 2025 that approximately 6.7 million adults were living with heart failure, with the number projected to exceed 8 million by 2030.

When medications are not very effective in the disease treatment and heart transplantation is not feasible, mechanical circulatory support devices are also used to assist cardiac circulation, which is used either to partially or to completely replace the function of a failing heart, mechanical support systems include VAD, Total Artificial Heart (TAH), extracorporeal Membrane Oxygenator (ECMO) Pumps, and Intra-Aortic Balloon Pumps (IABP).

The increasing prevalence and rising death cases due to the failure of the heart have increased the demand for VAD, as it can be used for both bridges to transplant as well as destination therapy.

Furthermore, to fuel the increasing demand for VAD, market players have been focusing on new product launches and the expansion of their production capacity. For instance, in June 2021, Abbott expanded the supply of its ventricular assist device, HeartMate 3, to fuel the growing demand. Such a scenario is anticipated to drive the global ventricular assist device market growth during the forecast period.

MARKET RESTRAINTS

High Cost Associated with the Use of VAD to Limit its Adoption

The limited availability of heart donors and the increasing prevalence of heart failure have increased the penetration of these devices. However, the high costs associated with the implantation of these devices have been limiting their adoption.

• For instance, in June 2026, RihlatMed stated that the average cost of LVAD treatment in India typically ranges from USD 30,000 to 60,000 USD, depending on treatment and device type.

Such high costs associated with the implantation of these devices have been restricting their adoption by the patient population globally.

Sometimes these devices might stop working efficiently after implantation. For instance, a VAD might not pump blood effectively, or the power supply might fail. These problems require immediate medical attention and may require the pump to be replaced. Such factors limit the product penetration.

Therefore, the high costs and other complications associated with the device might limit the device’s adoption in the forecast period.

MARKET OPPORTUNITIES

Expansion of Destination Therapy Among Non-Transplant-Eligible Patients to Create New Market Opportunities

In recent years, there has been an increasing demand for left ventricular assist devices (LVADs) as destination therapy (DT) as they provide long-term mechanical circulatory support to patients with advanced heart failure who are not suitable candidates for heart transplantation owing to advanced age, comorbidities, or other clinical factors.

• For instance, in November 2025, the Journal of American College of Cardiology (JACC) reported that destination-therapy intent has accounted for approximately 80.0% of U.S. LVAD implants in recent years.

Current CMS coverage includes FDA-approved LVADs for long-term mechanical circulatory support, including destination therapy, which is further creating significant opportunity for VADs as destination therapy (DT).

MARKET CHALLENGES

Risk of Bleeding, Infection, Thrombosis, and Other Device-Related Complications to Limit Adoption

Despite substantial improvements in VAD design and hemocompatibility, the device and treatment-related complications remain an important challenge to wider adoption of ventricular assist devices. Also, the patients receiving durable LVADs require prolonged anticoagulation and continuous device management, increasing overall treatment costs. Moreover, Several complications persist even with contemporary magnetically levitated devices.

• For instance, a May 2025 Cleveland Clinic study involving 431 HeartMate 3 recipients reported that device-related infections occurred in 136 patients.
• Similarly, a Journal of the American College of Cardiology (JACC) in July 2026 stated that MOMENTUM 3 analysis found gastrointestinal bleeding rates of 0.42 events per patient-year among recipients aged 70 years or older, compared with 0.12 among patients younger than 50 years.

This is potentially discouraging eligible patients and physicians from choosing VAD therapy, which is expected to pose a major challenge for the market’s expansion.

Segmentation Analysis

By Product

Increasing Implantations to Drive Growth of the LVAD Segment

Based on product, the market is segregated into left ventricular assist device (LVAD), right ventricular assist device, and bi-ventricular assist device.

The LVAD segment accounted for the highest market share in 2025 due to the number of implantation procedures amongst patients globally. Market players are focusing on developing these devices for patients with heart failure and other cardiovascular diseases, as they help the heart to function by supporting the chambers of the heart in patients.  For instance, in September 2025, AdventHealth joined the INNOVATE pivotal trial and performed its first BrioVAD implantation, expanding clinical evaluation of the next-generation durable LVAD.

The biventricular assist device (Bi-VAD) segment is expected to grow at a CAGR of 7.6% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Type of Flow

High Efficiency Associated with the Use of Continuous Flow Devices to Surge Segment Growth

Based on type of flow, the market is segmented into pulsatile flow and continuous flow.

The continuous flow segment held a significant market share in 2025 due to the benefits of continuous flow. Continuous flow devices have benefits such as lower maintenance, minimal noise, rare replacements, and a few moving parts. The benefits of continuous flow devices have been increasing their demand among physicians and researchers. To meet the demand in the market, the major players, such as Heart Inc., launched DuraHeart LVAD, a continuous flow device.

The pulsatile flow segment is projected to grow at a substantial CAGR of 9.2% during the forecast period.

By Application 

Growing Use of Long-Term Mechanical Circulatory Support to Drive Destination Theraphy Segment

In terms of application, the market is segmented into bridge to transplant (BTT), bridge to candidacy (BTC), destination therapy (DT), and bridge to recovery (BTR).

The destination therapy (DT) segment accounted for the highest ventricular assist device market share during 2025, owing to a rise in final-stage cardiac failure incidence. DT is an alternative to transplant that can improve functional capacity, extend patients' lives, and relieve symptoms of heart failure. LVADs have their application as destination therapy for the treatment of patients who cannot undergo heart transplantation. The limited availability of heart donors and complications associated with heart transplantation surgeries fueled the segment’s growth. Furthermore, the segment is expected to account for a 45.7% share of the market by 2026.

However, the bridge to transplant (BTT) segment is growing at a higher growth rate of 10.7% during the forecast period.

By End-user

Hospitals & Ambulatory Surgery Centers (ASCs) to Account for Largest Share Owing to Demand in Surgical Procedures

In terms of end-user, the market is segmented into hospitals & ASCs and specialty clinics & others. The hospitals & ASCs segment is expected to hold the dominant share in the market during the forecast period due to an increase in hospital stays of patients undergoing heart surgeries such as device placement or implant procedures.

The specialty clinics & others segment is expected to grow at a CAGR of 13.8% during the forecast period.

Ventricular Assist Device Market Regional Outlook

North America

To get more information on the regional analysis of this market, Download Free sample

North America dominated the global market and generated revenue of USD 0.75 billion in 2025, and in 2024, the regional market value was USD 0.69 billion. The dominance of this regional market is attributable to the growing prevalence of cardiovascular diseases and heart transplantation volumes in the region. Moreover, an increasing number of collaborations and agreements amongst the key players emphasizing the development of this market have been fueling the adoption of these devices in the region.

• For instance, according to the OPTN/SRTR 2024 Annual Data Report, the U.S. reached a record of 4,636 heart transplants in 2024, reflecting an 81.5% increase from 2013.

U.S. Ventricular Assist Device Market

In 2026, the U.S. is anticipated to reach USD 0.81 billion, accounting for approximately 49.3% of the global sales.

Europe

Europe is projected to record a CAGR of 10.1% during the forecast period, the second-highest globally. The market is expected to reach USD 0.51 billion in 2026. The region’s growth is attributed to higher investments for the development of ventricular assist devices and the presence of key players in the region. 

Asia Pacific

The Asia Pacific is likely to be the third-largest market with a value of USD 0.19 billion in 2026 and witness a fast-paced growth during the forecast period owing to advancements in healthcare facilities and favorable government policies. Medical device companies are making investments in the region for these devices to increase their adoption in the market, which is projected to boost the market growth.

Japan Ventricular Assist Device Market

Japan is projected to reach approximately USD 0.04 billion in revenue in 2026, representing nearly 2.4% of the global sales.

China Ventricular Assist Device Market

In 2026, China is anticipated to reach USD 0.08 billion, accounting for approximately 4.9% of the global sales.

India Ventricular Assist Device Market

In 2026, India is anticipated to reach USD 0.01 billion, accounting for approximately 0.7% of the global sales.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa accounted for a comparatively lower share of the market, with Latin America accounting for the value of USD 0.06 billion in 2026. The share is due to increasing penetration by key players in Latin America. Moreover, the Middle East & Africa market growth is attributed to awareness programs initiated by government organizations, leading to increased diagnosis and treatment rates for heart failure in the region.

COMPETITIVE LANDSCAPE

Key Industry Players

Companies with Strong Sales of VAD to Boost Market Competition

Abbott, ABIOMED, and Berlin Heart are among the prominent players in the market and captured a considerable global market share in 2025.

This is due to the companies’ strong sales of the devices and well-established brand reputation. Moreover, the company has a strong focus on strategic initiatives with an aim to expand its product offerings globally.

Other prominent players present in the market are focusing on receiving approval from regulatory bodies to expand the product portfolio and strengthen market shares during the forecast period.

Moreover, several companies have their products in the R&D stage. The launch of these products is expected to grab significant market shares in the coming years.

LIST OF KEY VENTRICULAR ASSIST DEVICE COMPANIES PROFILED

• Berlin Heart (Germany)
• ABIOMED (U.S.)
• Abbott (U.S.)
• magAssist Co., Ltd. (China)
• NIPRO (Japan)
• PulseCath (Netherlands)
• Suzhou Tongxin Medical Technology Co., Ltd. (China)

KEY INDUSTRY DEVELOPMENTS

• August 2026: Berlin Heart received U.S. FDA approval for a modification to the EXCOR Pediatric VAD blood pumps, allowing polyurethane to be used to seal the de-airing port plug.
• August 2026: Supira partnered with Hillcrest and Oklahoma Heart Institute to bring the SUPPORT II pivotal trial of its investigational pVAD system to Tulsa, Oklahoma.
• May 2025: Abbott received U.S. FDA approval for an updated HeartMate Touch Communication System, covering updated iPad hardware, operating system, and the HeartMate Touch application used with the HeartMate 3 LVAS.
• June 2024: magAssist and Wuhan Union Hospital jointly developed the MoyoAssist Extra-VAD, combining engineering and clinical expertise to commercialize a fully magnetically levitated extracorporeal VAD in China.
• November 2022: Jarvik Heart, Inc. conducted a clinical trial for its ventricular assist device named Jarvik 2015 with the aim of strengthening its product portfolio.
• September 2022: Abbott acquired Walk Vascular, LLC. Walk Vascular, LLC is a medical device company involved in developing a minimally invasive mechanical aspiration thrombectomy system to eliminate blood clots.
• September 2021: Abbott partnered with Cereno Scientific to use cutting-edge monitor device – CardioMEMS technology in an upcoming Phase II study with CS1 for the treatment of the rare disease pulmonary arterial hypertension and thrombotic indications.

REPORT COVERAGE

The research report provides a detailed competitive landscape. It includes the number of VAD implantations and key industry developments such as partnerships, mergers, and acquisitions. Additionally, it focuses on key points such as new product launches in the market. Furthermore, the report covers a regional analysis of different segments, company profiles of key market players, and market trends. The report consists of quantitative and qualitative insights contributing to the market growth.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Revenues and Market Share of Major Ventricular Assist Device Players

• VAD-attributable revenues of major manufacturers such as Abbott, Johnson & Johnson (Abiomed), Berlin Heart, HXCOREMED, BrioHealth/Tongxin, and other commercial players were collected from annual reports, filings, investor presentations, and company disclosures.
• Company market shares were estimated based on VAD revenues, product portfolio, implantation volumes, geographic reach, regulatory approvals, and commercial presence.
• Non-VAD revenues related to ECMO, IABP, high-risk PCI-only support, and other unrelated mechanical circulatory support applications were excluded.

Approach 2: VAD Implantation Volume × ASP Analysis

• Annual VAD implantation volumes were estimated across major countries using registries, transplant databases, hospital publications, clinical studies, and company disclosures.
• Volumes were assessed across LVAD, RVAD, BiVAD, continuous-flow, pulsatile-flow, BTT, BTC, DT, and BTR applications.
• Country-level market value was estimated by multiplying VAD implantation volumes by applicable manufacturer-level ASPs and adding qualifying replacement-component revenues.

Approach 3: Advanced Heart Failure and VAD-Eligible Patient Model

• Advanced and end-stage heart-failure populations, transplant waiting lists, transplant volumes, and donor-heart shortages were analyzed.
• The eligible population was adjusted for clinical suitability, reimbursement, VAD-center availability, affordability, and actual treatment penetration.
• Estimated VAD-treated patient volumes were multiplied by applicable ASPs to derive country and regional market values.

Approach 4: Installed Base and Replacement Revenue Analysis

• The installed VAD patient base was estimated using historical implantations, survival, transplantation, recovery, replacements, and reimplantations.
• Recurring revenues from controllers, batteries, drivelines, cannulae, and other VAD-specific components were incorporated where applicable.
• These estimates were reconciled with new-device sales to avoid double counting.

2. Top-Down Approaches

Approach 5: Parent and Adjacent Market Analysis

• Broader mechanical circulatory support and advanced heart-failure device markets were analyzed to estimate the share attributable specifically to VADs.
• Estimates were validated using implantation volumes, VAD penetration, manufacturer revenues, transplant activity, and regional healthcare infrastructure.
• Non-VAD products such as ECMO, IABP, total artificial hearts, pacemakers, ICDs, and CRT devices were excluded.

Approach 6: Parent and Adjacent Market Analysis

• Country-level cardiovascular spending, VAD-center capacity, transplant infrastructure, reimbursement, and healthcare access were assessed.
• Countries with limited direct data were benchmarked against comparable markets using heart-failure burden, treatment capacity, VAD penetration, and healthcare expenditure.
• Country estimates were aggregated to regional and global totals.

3. List of Key Sources

• Annual reports, SEC filings, investor presentations, and company disclosures.
• STS INTERMACS, EUROMACS, ISHLT, OPTN/UNOS, and national transplant/VAD registries.
• FDA, CMS, European Commission, NICE, PMDA, MHLW, NMPA, CDSCO, TGA, and national health authorities.
• WHO, OECD, Eurostat, World Bank, clinical publications, reimbursement policies, and hospital disclosures.

4. Market Validation and Triangulation

• Results from all approaches were compared to identify potential overestimation or underestimation.
• Manufacturer revenues were cross-checked against implantation volumes, ASPs, installed base, replacement demand, and country-level clinical utilization.
• Regional estimates were reconciled to ensure consistency with the global market size.

5. Primary Interviews

Supply Side Interviews: 60%

• Key Respondents:
  • VAD manufacturers, component suppliers, distributors, sales executives, product managers, regulatory professionals, and business development executives.
  • Interviews focused on revenues, unit sales, ASPs, product mix, geographic reach, competitive shares, and future growth.

Demand Side Interviews: 40%

• Key Respondents:
  • Cardiothoracic surgeons, heart-failure cardiologists, transplant surgeons, VAD coordinators, hospital procurement teams, and cardiac-center administrators.
  • Interviews focused on implantation volumes, treatment pathways, device selection, reimbursement, patient eligibility, purchasing trends, and expected VAD adoption.